MYOV - Myovant Sciences rises on FDA approval for relugolix

According to the FDA website, Myovant Sciences ([[MYOV]] +5.0%) has received the approval for MYFEMBREE (relugolix; estradiol; norethindrone) tablets on priority review.In August, the company announced the FDA acceptance of its marketing application for relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.The regulator had set a PDUFA date of June 1, 2021.

For further details see:

Myovant Sciences rises on FDA approval for relugolix